Skip to content

Comparison of two regimens of fluconazol in treatment of cutaneous lieshmaniasis

Comparison of two regimens of fluconazol 200 mg and 400 mg daily in the treatment of cutaneous lieshmaniasis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138710221542N1
Enrollment
94
Registered
2009-05-18
Start date
2007-12-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous leishmaniasis. Cutaneous leishmaniasis

Interventions

Intervention 1: First group: fluconazol 200mg/daily for six weeks. Intervention 2: Second group: fluconazol 400mg/daily for six weeks.
Treatment - Drugs
First group: fluconazol 200mg/daily for six weeks
Second group: fluconazol 400mg/daily for six weeks

Sponsors

Shiraz University of Medical Scienses
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age over 12 years, positive PCR for leishmanisis and no treatment in two months ago, duration of disease is lower than 4 months. Exclusion criteria: pregnancy, breast feeding, possibility of pregnancy in future, number of lesion over ten, history of liver disease and high BUN or Cr.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Reepithelialization. Timepoint: every two week. Method of measurement: observation.;Size of lesion. Timepoint: every two week. Method of measurement: with ruler.;Induration of lesion. Timepoint: every two week. Method of measurement: physical examination.

Secondary

MeasureTime frame
Rising of liver enzyme, BUN and Cr. Timepoint: every two week. Method of measurement: Blood sample and laboratory measurment.;Nausea and vomitting. Timepoint: every two week. Method of measurement: History.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHayati Fariborz MD

Shiraz University of Medical Sciences

fhayati @sums.ac.ir dr.fariborz hayati @gmail .com+98 71 1231 9049

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026